|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
Melanoma is the deadliest of all the skin cancers. Its prevalence continues to grow year after year. The risk of melanoma increases with age, but is now occurring more frequently in younger patients. It is estimated that in 2020 over 100,350 new cases of Melanoma were diagnosed leading to over 6,000 deaths from this disease. This puts melanoma in the top ten list of cancers for men and women in the United States. This educational activity will provide an overview of the diagnosis, epidemiology, risk factors, pathology, and staging of melanoma. This activity will include an in-depth review of treatments for melanoma. Adverse events, appropriate patient monitoring, and adherence will also be discussed.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
- Describe the epidemiology, pathophysiology, and risk factors associated with melanoma
- Discuss the screening, diagnosis, and staging of melanoma
- Outline treatment considerations and the mechanism of action of chemotherapy and supportive therapies
- Describe the side effect and monitoring parameters associated with therapies managed through specialty pharmacy
- Discuss counseling strategies to maximize compliance and adherence
Megan Brafford May, Pharm.D., BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Megan Brafford May does not have any relevant commercial and/or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 03-13-2020
Expiration Date: 03-13-2023
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-202-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.